CLDI

Business Context and Reporting Period

Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Calidi is a clinical-stage immuno-oncology company developing allogeneic stem cell-based platforms to deliver oncolytic viruses for cancer treatment. Key programs include CLD-101 (NeuroNova) for High Grade Glioma and CLD-201 (SuperNova) for advanced solid tumors. The company has no approved products and generates no product revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 31% for the six months ended June 30, 2024, compared to the same period in 2023. This was primarily driven by a significant reduction in "Other income (expenses), net" due to favorable changes in the fair value of debt and derivatives, partially offset by a decrease in grant income from the California Institute for Regenerative Medicine (CIRM).
• Operating Expenses: Total operating expenses increased by 5% year-over-year for the six-month period. Research and Development (R&D) expenses decreased by 15% due to lower clinical trial service fees, while General and Administrative (G&A) expenses increased by 24% due to higher legal fees, insurance costs, and consulting fees.
• Liquidity Position: Cash and restricted cash decreased from $2.17 million at December 31, 2023, to $1.05 million at June 30, 2024, reflecting a net cash outflow of $1.11 million for the period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of issuance. The company does not have sufficient cash to fund operations for the next year without raising additional capital.
• Capital Raising Activities:
  • April Public Offering: Raised approximately $6.1 million gross proceeds.
  • May Inducement Offer: Raised approximately $2.1 million gross proceeds through the exercise of existing warrants at a reduced price.
  • Subsequent Events: In July 2024, the company completed a private placement raising $1.0 million and secured a $0.6 million loan. Additionally, a 1-for-10 reverse stock split was effected on July 15, 2024.
• Debt Obligations: The company carries significant related-party debt, including term notes and bridge loans, with interest rates ranging from 12% to 24% (some amended to 14% in August 2024). Total debt carrying value is approximately $4.9 million.
• Legal Proceedings: The company is involved in litigation with a former Chief Accounting Officer/Interim CFO regarding alleged constructive discharge and defamation, and a settled dispute with physicians regarding stock options (settled via issuance of restricted shares and warrants).
• Unusual Items: The net loss attributable to common stockholders includes a $1.67 million "deemed dividend" related to the May Inducement Offer warrant modification.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.05 million cash balance against the stated operating burn rate and the timeline for securing additional funding.
• Dilution Risk: Review the impact of the 1-for-10 reverse stock split and the large number of outstanding warrants (approx. 7.86 million) and options on future share count and ownership dilution.
• Debt Maturity: Assess the maturity dates and repayment terms of the $4.9 million in outstanding debt, particularly the related-party term notes due in 2025.
• Going Concern Status: Monitor subsequent filings for evidence of successful capital raises to mitigate the substantial doubt expressed in the 10-Q.
• Legal Exposure: Track the status of the lawsuit filed by the former CFO and any potential financial impact from the settlement.